NEUP.US Neuphoria Therapeutics Inc

Healthcare Biotechnology USA Stocks
2.55 USD
Close of Nov 15, 2026
2.45 5.53
Market cap
USD 13.8M
P/E
-
P/B
0.55x
ROE
-54.7%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Jun 2026.

Is NEUP.US undervalued?

Graham number

The Graham number of Neuphoria Therapeutics Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Neuphoria Therapeutics Inc fundamental analysis

No fundamental analysis for Neuphoria Therapeutics Inc yet.

Neuphoria Therapeutics Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Neuphoria Therapeutics Inc

Neuphoria Therapeutics Inc., a clinical stage biopharmaceutical company, develops novel allosteric ion channel modulators for patients with serious central nervous system disorders in Australia. Its lead product candidate is BNC210, an oral, proprietary, selective negative allosteric modulator of the alpha7 nicotinic acetylcholine receptor for post-traumatic stress disorder. The company also develops Merck alpha7 positive allosteric modulators. It has a research collaboratio…

Full company profile